Oil prices fall below 100 yuan+Besent calls out, U.S. Treasury yields retreat from 2002 highs
U.S. Treasury yields have retreated from their highest levels since 2002.
According to Zhihui Finance APP, U.S. Treasury yields have retreated from their highest levels since 2002, as oil prices fell below $100 per barrel and U.S. Treasury Secretary Scott Besant insisted that the government debt burden is manageable. The yields on 10-year and 30-year U.S. Treasury bonds dropped by 3 and 4 basis points, to 5.27% and 5.63% respectively, while the 2-year yield remained largely unchanged. On Tuesday, oil prices declined as signs emerged that more crude oil is being supplied through the Strait of Hormuz.
This signals a pause in the global bond market sell-off, which previously continued due to concerns over inflation triggered by conflict between the U.S. and Iran, and a rising expectation of further monetary tightening by the Federal Reserve.
Besant attempted to reassure investors, stating that a combination of economic growth and spending restrictions will “soon” begin to change the U.S. government’s borrowing trajectory. In a fireside chat in Pennsylvania on Monday evening, he said the government would start “reversing this trend.”
Voices of Doubt: Deficit Unsolved, Reassurance Falls Short
Nevertheless, the market remains skeptical of Besant’s statements and is reluctant to declare that the bond market sell-off has ended.
Macquarie strategist Gareth Berry commented: “Given the deficit is as high as 6% and there are no plans to cut the deficit, the market may remain very doubtful. Speaking about targets is not the same as having a plan.”
Schroders fund manager James Ling said he is focused not only on crude prices. “To see a meaningful rebound across the entire curve, the primary condition is for energy prices to start falling,” he said. “It’s not just about crude oil prices, but also refined product prices.”
Additionally, Bridgewater founder Ray Dalio warned that the U.S. is approaching the limit of the debt cycle and, if spending continues to exceed earnings, may face a crisis within three years. He said U.S. Treasuries are vulnerable to decreased demand from China and Japan (the two largest foreign holders of U.S. debt).
However, HSBC strategists believe the market’s bet on roughly 80 basis points of Federal Reserve rate hikes by 2027 is “excessive,” but they still maintain that the yield spread between 5-year and 30-year U.S. Treasuries will widen. HSBC U.S. rates strategist Dheeraj Narula wrote in a report: “We believe that surging volatility, combined with historical data showing a lack of clear technical resistance at these levels, has led many investors to adopt a wait-and-see stance, although the appeal of higher long-term yields is increasingly evident.”
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
XRP Ledger Prints 386% Comeback in Important Metric
BUZZ—US Stock Market Updates—MYR Group, Spyre Therapeutics, AMD
Search string for querying individual stock trends: STXBZ "Today's Outlook" newsletter: https://refini.tv/3LI4BU7 "Morning News Briefing": https://refini.tv/3dKUyB8 Reuters, October 6 - U.S. stock index futures rose on Tuesday as Treasury yields retreated from multi-year highs and oil prices declined, providing a bit of relief for investors ahead of the quarterly earnings season. ** MYR Group MYRG.O: Market Spotlight — Jefferies upgraded MYR Group to "Buy"; stock price rose nL4N45S0PK ** Spyre Therapeutics SYRE.O: Market Action — Spyre Therapeutics shares fell due to a $350 millions stock offering nL6N45S0PG ** AMD.O: Market Action — AMD shares rose on plans to increase chip supply nL4N45S0Q7 ** Constellation Energy CEG.O: Highlight — Alphabet reportedly close to signing a multi-year nuclear energy deal, Constellation Energy shares climbed nL6N45S0HX ** Nike NKE.N: Highlight — Berenberg downgraded Nike to "Sell"; shares declined nL6N45S0KB ** Option Care Health OPCH.O: Highlight — Option Care Health surged after reportedly receiving a buyout offer exceeding $5 billions nL4N45S0L5 ** Freshworks Inc FRSH.O: Market Action — Freshworks stock advanced as it is set to be added to the S&P SmallCap 600 nL4N45S0IT (For the convenience of non-English speakers, Reuters automatically translates its reports into various other languages. As automatic translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translations and provides them solely for readers' convenience. Reuters is not responsible for any damage or loss caused by the use of automatic translation features.)
Top Premarket Decliners
07:38 AM EDT, 10/06/2026 (MT Newswires) -- Armada Acquisition Corp. II (XRPN) shares were down more than 16% in premarket activity Tuesday following a nearly 2% fall in the prior session. HeartSciences (HSCS) stock was 14% lower after a 1.4% gain in the prior session. WISeSat.Space (SAIQ) shares were down 13% after a 260% rise at the previous close. CTW (CTW) stock was 7% lower after remaining flat at Monday's close. Republic Power Group (RPGL) shares were down 4% after a regulatory filing showed that the company and its institutional investor mutually agreed to terminate an additional investment right, with Republic paying a $250,000 termination fee.
BUZZ - Spyre Therapeutics shares tumble due to $350 million stock offering
On October 6, Spyre Therapeutics (SYRE.O) shares fell 4.1% to $88.90 in pre-market trading after the company priced a $350 million follow-on offering. The biotechnology firm announced late Monday that it was issuing approximately 4.1 million shares at $85 per share, an 8.3% discount to its last closing price. The company plans to use the net proceeds to advance its programs in gastroenterology, rheumatology, and dermatology, as well as to move a new project—SPY072—into later-stage development for the chronic skin disease hidradenitis suppurativa, among other uses. Jefferies, TD Cowen, Leerink, and Stifel are acting as joint book-running managers for the offering. On September 30, Merck’s (MRK.N) tulisokibart achieved success in a dermatology clinical trial, after which SYRE shares climbed about 5%. Analysts noted that the trial data supports SYRE's experimental candidate targeting the same signaling pathway. Headquartered in Waltham, Massachusetts, SYRE had around 88.2 million shares outstanding prior to the offering. As of Monday’s close, the stock had risen 183% year-to-date. According to LSEG data, 16 of 17 analysts rate the stock a “strong buy” or “buy,” with one analyst rating it “hold.” The median price target is $123. (For the convenience of non-English speakers, Reuters provides automated translations of its reports. Automated translations may contain errors or lack necessary context; Reuters makes no guarantee regarding the accuracy of machine translations and provides them for readers’ convenience only. Reuters accepts no liability for any damage or loss resulting from the use of automated translation.)
Crypto prices
More
